This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barry, A L
Right arrow Articles by Fuchs, P C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barry, A L
Right arrow Articles by Fuchs, P C

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1991 May; 35(5): 955-960

In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

A L Barry and P C Fuchs

Clinical Microbiology Institute, Tualatin, Oregon 97062.

ABSTRACT

The in vitro activity of sparfloxacin was compared with those of tosufloxacin, ciprofloxacin, and fleroxacin against 730 bacterial isolates representing 49 different species. Sparfloxacin and ciprofloxacin had similar spectra of activity, but sparfloxacin was less active against Pseudomonas aeruginosa and more active against many gram-positive cocci and anaerobic bacteria. Tosufloxacin MICs were generally 8- to 16-fold lower than those for sparfloxacin or ciprofloxacin. All four fluoroquinolones were active against nalidixic acid-susceptible strains of the family Enterobacteriaceae (MIC for 90% of the isolates [MIC90], less than or equal to 0.25 micrograms/ml) but nalidixic acid-resistant strains were less susceptible (MIC90, greater than or equal to 4.0 micrograms/ml). Against Pseudomonas aeruginosa isolates, MIC90s were 1.0 micrograms/ml for tosufloxacin, 2.0 micrograms/ml for ciprofloxacin, and 4.0 micrograms/ml for sparfloxacin. Against Enterococcus faecalis, sparfloxacin and ciprofloxacin MIC90s were 1.0 and 2.0 micrograms/ml, respectively. MIC90s for ciprofloxacin-susceptible Staphylococcus aureus were 0.016 micrograms/ml for tosufloxacin, 0.06 micrograms/ml for sparfloxacin, and 0.5 micrograms/ml for both ciprofloxacin and fleroxacin. With four species of gram-negative bacilli, mutants resistant to two to four times the sparfloxacin MIC occurred spontaneously at frequencies of 10(-7) to 10(-9): single-step high-level resistance was not observed. In vitro-selected sparfloxacin-resistant mutants displayed cross-resistance to other quinolones, as did clinical isolates of ciprofloxacin-resistant S. aureus. Tosufloxacin MICs with broth microdilution methods were four- to eightfold greater than those obtained with agar dilution methods. The two procedures gave comparable results when sparfloxacin or ciprofloxacin was being tested.


Antimicrob Agents Chemother. 1991 May; 35(5): 955-960




This article has been cited by other articles:

  • Peric, M., Jacobs, M. R., Appelbaum, P. C. (2004). Antianaerobic Activity of a Novel Fluoroquinolone, WCK 771, Compared to Those of Nine Other Agents. Antimicrob. Agents Chemother. 48: 3188-3192 [Abstract] [Full Text]  
  • Hoellman, D. B., Kelly, L. M., Jacobs, M. R., Appelbaum, P. C. (2001). Comparative Antianaerobic Activity of BMS 284756. Antimicrob. Agents Chemother. 45: 589-592 [Abstract] [Full Text]  
  • Ednie, L. M., Jacobs, M. R., Appelbaum, P. C. (1998). Activities of Gatifloxacin Compared to Those of Seven Other Agents against Anaerobic Organisms. Antimicrob. Agents Chemother. 42: 2459-2462 [Abstract] [Full Text]